Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Shares Outstanding (2018 - 2024)

Historic Shares Outstanding for Autolus Therapeutics (AUTL) over the last 4 years, with Q4 2024 value amounting to $34425.0.

  • Autolus Therapeutics' Shares Outstanding changed 0.0% to $34425.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $34425.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $34425.0 for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Autolus Therapeutics reported Shares Outstanding of $34425.0 as of Q4 2024, which was down 0.0% from $34425.0 recorded in Q4 2023.
  • Over the past 5 years, Autolus Therapeutics' Shares Outstanding peaked at $173.1 million during Q4 2022, and registered a low of $34425.0 during Q4 2023.
  • Over the past 3 years, Autolus Therapeutics' median Shares Outstanding value was $34425.0 (recorded in 2023), while the average stood at $57.7 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Shares Outstanding soared by 9038.46% in 2022, and later crashed by 10000.0% in 2023.
  • Over the past 4 years, Autolus Therapeutics' Shares Outstanding (Quarter) stood at $90.9 billion in 2021, then soared by 90.38% to $173.1 billion in 2022, then tumbled by 100.0% to $34425.0 in 2023, then changed by 0.0% to $34425.0 in 2024.
  • Its Shares Outstanding was $34425.0 in Q4 2024, compared to $34425.0 in Q4 2023 and $173.7 billion in Q2 2023.